参与阿尔茨海默病进展的关键因素
Dania Khalid1, Amber Afroz1, Hammad Ismail1
1Department of Biochemistry and Biotechnology, University of Gujrat, Gujrat, Pakistan.
Central nervous system agents in medicinal chemistry
|September 5, 2025
概括
由于蛋白质异常和神经递质失衡,阿尔茨海默病 (AD) 导致认知能力下降. 研究探讨天然产品与糖尿病的联系,寻找潜在的治疗策略.
科学领域:
- 神经科学
- 生物化学
- 遗传学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知功能,特别是在60岁以上的人群中,年轻人中发病率越来越高.
- 艾滋病的确切原因尚不清楚, 阻碍了针对性的药物开发.
- 关键的相关因素包括改变的蛋白,粉样β,胆能受体,神经递质失衡 (多巴胺,血清素),线粒体功能障碍和炎症.
研究的目的:
- 审查阿尔茨海默病的多面生物基础.
- 突出新兴研究领域,包括阿尔茨海默病与糖尿病之间的联系.
- 探索天然产品在阿尔茨海默病治疗中的潜力.
主要方法:
- 审查现有的科学文献和转录组学/蛋白组学分析.
- 研究AD的遗传和蛋白质失调.
- 检查参与阿尔茨海默病变的细胞路径.
主要成果:
- 通过转录组和蛋白组识别涉及AD的相互连接的基因和蛋白质.
- 证据表明阿尔茨海默病与糖尿病之间存在联系.
- 识别线粒体功能障碍,信号和炎症是显著的贡献者.
结论:
- 阿尔茨海默病的发病过程复杂,涉及遗传,蛋白质和细胞通路的破坏.
- 这种与糖尿病的联系为研究提供了新的途径.
- 天然产品有望成为治疗阿尔茨海默病及其症状的未来药物.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Role of Neurotransmitters in Memory
959
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
959
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K


